anti-CD19 CAR-NK

BIOLOGICAL2 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

B-cell Non Hodgkin Lymphoma

Phase 1

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityB-cell Non Hodgkin Lymphoma

Start: 2021-05-01End: 2024-05-01Target: 25Updated: 2021-05-14

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

RecruitingNCT05472558

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityB-cell Non Hodgkin Lymphoma

Start: 2022-07-26End: 2026-12-31Target: 48Updated: 2025-03-04

Related Papers

Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

2025-04-1817 citations

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Blood2024-11-054 citations